Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $49 from $28 and keeps a Buy rating on the shares. The firm noted the company announced the re-prioritization of its pipeline development with acne taking the lead. The company raised $175M to achieve this new strategy and the company hosted a KOL call to broaden investor knowledge of the acne market and unmet need.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer
- Sagimet Therapeutics: Buy Rating Reiterated on Denifanstat’s First-Line Acne Potential; $28 Price Target Unchanged
- Sagimet Biosciences management to meet virtually with Clear Street
- Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim
- 3 Penny Stocks to Watch Now, 4/28/26